We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.
about
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaEribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.Everolimus treatment in advanced solid tumors: a personal viewResponse to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.One-year outcomes of a BioMime™ Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in all-comers coronary artery disease patients: The meriT-3 studyEribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.Pomalidomide: when expectations are understated.3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience.Eribulin in 'field practice': an overview of the Italian experience.
P2860
Q26783514-F99DD45B-FD3A-4AF9-84B2-889437E1DC6DQ38686622-71D55DF5-E6CA-4421-8002-DBD67C2326D0Q38766508-A118FF09-7E45-4A5F-9BD2-A304D01B87ABQ38766512-1AB9F0CC-DDB8-4021-8BD5-80BABF7DF175Q38777011-1232EEDD-3BEB-434F-930E-9E37BADC3925Q38978435-6092E134-2177-44D5-A631-BA3A18C4D5BCQ39009684-06757E1A-8A52-4AD2-90B2-0F0B854EDE88Q39257421-AD289D06-165E-4A27-B8EF-4551B3DCC19EQ39289531-040326CA-19C3-4C6C-9F77-191C99A3AE96Q48062402-EF66533C-1F3F-461C-912E-D20A10F9FB8DQ48329409-594A4E8D-AF20-404A-863D-75A568904770Q48420553-FFD42182-2069-4F12-A0C2-55FE5C9F0886
P2860
We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
We need both randomized trials ...... second-line therapy for mRCC.
@en
We need both randomized trials ...... second-line therapy for mRCC.
@nl
type
label
We need both randomized trials ...... second-line therapy for mRCC.
@en
We need both randomized trials ...... second-line therapy for mRCC.
@nl
prefLabel
We need both randomized trials ...... second-line therapy for mRCC.
@en
We need both randomized trials ...... second-line therapy for mRCC.
@nl
P2860
P356
P1433
P1476
We need both randomized trials ...... second-line therapy for mRCC.
@en
P2093
Giovanni Pappagallo
Mimma Rizzo
P2860
P304
P356
10.2217/FON.14.182
P407
P577
2014-08-21T00:00:00Z